Goldstein Cory E, Weijer Charles, Brehaut Jamie C, Fergusson Dean A, Grimshaw Jeremy M, Horn Austin R, Taljaard Monica
Rotman Institute of Philosophy, Western University, 1151 Richmond St., London, ON, N6A 5B7, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
BMC Med Ethics. 2018 Feb 27;19(1):14. doi: 10.1186/s12910-018-0253-x.
Pragmatic randomized controlled trials (RCTs) are designed to evaluate the effectiveness of interventions in real-world clinical conditions. However, these studies raise ethical issues for researchers and regulators. Our objective is to identify a list of key ethical issues in pragmatic RCTs and highlight gaps in the ethics literature.
We conducted a scoping review of articles addressing ethical aspects of pragmatic RCTs. After applying the search strategy and eligibility criteria, 36 articles were included and reviewed using content analysis.
Our review identified four major themes: 1) the research-practice distinction; 2) the need for consent; 3) elements that must be disclosed in the consent process; and 4) appropriate oversight by research ethics committees. 1) Most authors reject the need for a research-practice distinction in pragmatic RCTs. They argue that the distinction rests on the presumptions that research participation offers patients less benefit and greater risk than clinical practice, but neither is true in the case of pragmatic RCTs. 2) Most authors further conclude that pragmatic RCTs may proceed without informed consent or with simplified consent procedures when risks are low and consent is infeasible. 3) Authors who endorse the need for consent assert that information need only be disclosed when research participation poses incremental risks compared to clinical practice. Authors disagree as to whether randomization must be disclosed. 4) Finally, all authors view regulatory oversight as burdensome and a practical impediment to the conduct of pragmatic RCTs, and argue that oversight procedures ought to be streamlined when risks to participants are low.
The current ethical discussion is framed by the assumption that the function of research oversight is to protect participants from risk. As pragmatic RCTs commonly involve usual care interventions, the risks may be minimal. This leads many to reject the research-practice distinction and question the need for informed consent. But the function of oversight should be understood broadly as protecting the liberty and welfare interest of participants and promoting public trust in research. This understanding, we suggest, will focus discussion on questions about appropriate ethical review for pragmatic RCTs.
实用性随机对照试验(RCT)旨在评估干预措施在现实临床环境中的有效性。然而,这些研究给研究人员和监管机构带来了伦理问题。我们的目标是确定实用性RCT中的一系列关键伦理问题,并突出伦理文献中的空白。
我们对涉及实用性RCT伦理方面的文章进行了范围综述。在应用检索策略和纳入标准后,纳入了36篇文章并使用内容分析法进行综述。
我们的综述确定了四个主要主题:1)研究与实践的区分;2)知情同意的必要性;3)同意过程中必须披露的要素;4)研究伦理委员会的适当监督。1)大多数作者拒绝在实用性RCT中区分研究与实践。他们认为这种区分基于这样的假设,即研究参与给患者带来的益处比临床实践少,风险比临床实践大,但在实用性RCT中这两者都不成立。2)大多数作者进一步得出结论,当风险较低且无法获得同意时,实用性RCT可以在没有知情同意或采用简化同意程序的情况下进行。3)支持知情同意必要性的作者主张,只有当研究参与与临床实践相比带来额外风险时才需要披露信息。对于是否必须披露随机分组,作者们存在分歧。4)最后,所有作者都认为监管监督繁琐,是开展实用性RCT的实际障碍,并认为当对参与者的风险较低时,监督程序应简化。
当前的伦理讨论是基于研究监督的功能是保护参与者免受风险这一假设展开的。由于实用性RCT通常涉及常规护理干预,风险可能极小。这导致许多人拒绝区分研究与实践,并质疑知情同意的必要性。但监督的功能应被广泛理解为保护参与者的自由和福利利益,并促进公众对研究的信任。我们认为,这种理解将使讨论聚焦于实用性RCT适当伦理审查的相关问题。